MG Clinical Trials in Miami, Florida
7 recruitingMiami, Florida
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled10 locationsNCT07294170
Recruiting
Phase 2
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled9 locationsNCT07284420
Recruiting
Phase 1Phase 2
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
MGMT-Unmethylated GlioblastomaHigh Grade GliomaMGMT-Methylated Glioblastoma
University of California, San Francisco70 enrolled5 locationsNCT06504381
Recruiting
Phase 4
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
New Onset Generalized Myasthenia Gravis (gMG)
argenx30 enrolled18 locationsNCT06909214
Recruiting
Phase 2
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Brain CancerGlioblastomaGlioblastoma Multiforme+4 more
Baptist Health South Florida190 enrolled1 locationNCT06991101
Recruiting
Phase 1Phase 2
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Myasthenia GravisGeneralized MyastheniaAChR Myasthenia Gravis+1 more
COUR Pharmaceutical Development Company, Inc.54 enrolled17 locationsNCT06106672